Clinical trials: Proteinuric Kidney Diseases
Lupus Nephritis, Immunosuppression
Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis
This a single-centre, one-arm, open-label pilot study. Eligible patients with mild proteinuric flares of lupus nephritis Class III/IV±V are received sirolimus without changing previous immunosuppressive medication during 12-week…
- Conditions
- Lupus Nephritis, Immunosuppression, Effect of Drug
- Trial name
- NCT04892212
- Testing
- Sirolimus
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Chronic Kidney Disease
Remission Clinic in Proteinuric Chronic Nephropathies
Most chronic kidney diseases have a progressive evolution characterized by the gradual loss of glomerular filtration rate (GFR), electrolytic imbalance, reduced erythropoietin synthesis and activation of vitamin D.
- Trial name
- NCT02721342
- Testing
- Ramipril, Irbesartan and Atorvastin
- Where
- 13 sites in Italy
- Volunteers
- 1,500 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
SGLT 2 Inhibitors, Pediatric Kidney Disease
Efficacy and Safety of Dapagliflozin in Children With Proteinuria
This interventional study investigates the efficacy of dapagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, in pediatric patients with renal disease.
- Conditions
- SGLT 2 Inhibitors, Pediatric Kidney Disease, Proteinuric Diseases, Dapagliflozin (Forxiga)
- Trial name
- NCT07204743
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
- Where
- Palestinian Territories
- Volunteers
- 10 people
- Sponsor
- Al-Quds University
IgA Nephropathy, Focal Segmental Glomerulosclerosis
Atrasentan in Patients With Proteinuric Glomerular Diseases
The AFFINITY Study is a phase 2, open-label, basket study to evaluate the efficacy and safety of atrasentan in patients with proteinuric glomerular disease who are at risk of progressive loss of renal function.
- Conditions
- IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease
- Trial name
- AFFINITY (NCT04573920)
- Testing
- Atrasentan
- Where
- 33 sites in United States, Australia and 4 more
- Volunteers
- 103 people
- Sponsor
- Novartis Pharmaceuticals
IgA Nephropathy
Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade
Study objective: To investigate the potential anti-proteinuric efficacy of aliskiren, a novel direct renin inhibitor (DRI), in addition to angiotensin receptor blocker (ARB) in immunoglobulin A nephropathy (IgAN) patients at risk…
- Trial name
- NCT00922311
- Testing
- Aliskiren
- Where
- 2 sites in China
- Volunteers
- 25 people
- Sponsor
- The University of Hong Kong
Pregnancy Complications, Proteinuria in Pregnancy
Sonoclot to Evaluate Thrombotic Risk in Proteinuric Pregnancy
There is a lack of consensus on whether women with proteinuric kidney disease benefit from prophylactic anticoagulation during pregnancy to reduce the risk of venous thromboembolism.
- Conditions
- Pregnancy Complications, Proteinuria in Pregnancy, Chronic Kidney Diseases, Venous Thromboembolism
- Trial name
- NCT05108389
- Testing
- Viscoelastic haemostasis monitor output
- Where
- United Kingdom
- Volunteers
- 13 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Proteinuria, Diabetic Nephropathy
FGF-23 and Endothelial Dysfunction in Diabetic Proteinuric Patients
There is no data about the effects of Renin angiotensin system blockage (RAS) on FGF23 and ADMA levels in diabetic patients with proteinuria.
- Conditions
- Proteinuria, Diabetic Nephropathy, Chronic Kidney Disease
- Trial name
- NCT01703234
- Testing
- Ramipril
- Where
- Turkey (Türkiye)
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Gulhane School of Medicine
Chronic Nephropathy, Proteinuria
Statins in Proteinuric Nephropathies
End stage renal disease (ESRD) is rapidly growing worldwide. Patients with ESRD have increased morbidity and mortality mostly because of a dramatic excess of cardiovascular disease.
- Conditions
- Chronic Nephropathy, Proteinuria, Hypertension
- Trial name
- ESPLANADE (NCT00199927)
- Testing
- Fluvastatin, standard therapy
- Where
- 16 sites in Italy
- Volunteers
- 217 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Chronic Kidney Disease, Unspecified
Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study)
The purpose of this study is to estimate the differences between albuminuria values determined as Urine Albumin-to-Creatinine Ratio (UACR)(log transformed) from baseline to last observation caused by paricalcitol between the…
- Trial name
- PALIFE (NCT01820078)
- Testing
- Experimental arm, Comparator Arm
- Where
- 25 sites in Spain
- Volunteers
- 127 people
- Sponsor
- Fundación Renal Iñigo Alvarez De Toledo
Proteinuric Kidney Disease, Diabetic Nephropathy
Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease
Primary Hypothesis: Aldosterone breakthrough will occur at a far lower frequency during renin inhibition (0-10% over 9 months), alone or in combination with an ARB, compared to conventional ARB therapy (35-45% over 9 months).
- Conditions
- Proteinuric Kidney Disease, Diabetic Nephropathy, Hypertensive Nephrosclerosis, IgA Nephropathy
- Trial name
- NCT01129557
- Testing
- Aliskiren, Valsartan
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Columbia University
Hypertension, Chronic Kidney Disease
Effects of Low Sodium Intake on the Anti-proteinuric Efficacy in Hypertensive Patient With Olmesartan
Purpose of this study 1. Intensive education for low salt diet will be enhance the anti-proteinuric effect of Olmesartan, a popular anti-hypertensive drug of angiotensin II receptor blocker, in Koreans compared to conventional…
- Conditions
- Hypertension, Chronic Kidney Disease, Microalbuminuria
- Trial name
- ESPECIAL (NCT01552954)
- Testing
- Intensive education of low salt diet
- Where
- 7 sites in South Korea
- Volunteers
- 269 people
- Sponsor
- Seoul National University Bundang Hospital
Proteinuric Kidney Disease
Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without Comorbidities
The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).
- Trial name
- AMPLIFIED (NCT06794996)
- Testing
- Inaxaplin
- Where
- 35 sites in United States
- Volunteers
- 42 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
Proteinuria, Kidney Diseases
Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease
The purpose of this study is to determine whether traditional Chinese medicine, Gu Shen Juan Yu Formula, as complementary treatment is safe and effective in the treatment of Inherited Proteinuric Kidney Disease.
- Conditions
- Proteinuria, Kidney Diseases, Hereditary Nephropathy
- Trial name
- NCT05759754
- Testing
- TCM+ Routine Therapy, Routine Therapy
- Where
- 9 sites in China
- Volunteers
- 72 people
- Sponsor
- Children's Hospital of Fudan University
Proteinuric Diseases
Phenylbutyrate in Proteinuric Nephropathies
The purpose of this study is to determine whether sodium phenylbutyrate can reduce Lcn2 urinary expression in proteinuric patients.
- Trial name
- PIRATE (NCT02343094)
- Testing
- PBA 7,5g/d, PBA 15g/d
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hypercholesterolemia, Chronic Nephropathy
Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy
The purpose of this study is to determine whether, in patients with chronic proteinuric nephropathy and dyslipidemia, ezetimibe-simvastatin combined therapy is more effective than statin alone to achieve the optimum lipid…
- Trial name
- VICTORY (NCT00861731)
- Testing
- simvastatin, EZE/simvastatin
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Azienda Ospedaliero Universitaria di Sassari
Proteinuria
A Crossover Pilot Study of the Effect of Amiloride on Proteinuria
This cross-over study is designed to test the hypothesis that amiloride will reduce urinary protein excretion and protect the kidney from rapid progression in proteinuric kidney disease.
- Trial name
- NCT02522650
- Testing
- Amiloride, Triamterene
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Georgetown University
Proteinuric Renal Disease
A Study Of Oral Paricalcitol To Treat Proteinuric Renal Disease
Diabetic Nephropathy and other proteinuric renal diseases are the major cause of kidney disease in the United States. The degree of proteinuria is associated with risk for renal disease progression and cardiovascular outcomes.
- Trial name
- NCT00469625
- Testing
- paricalcitol (initial dose 1 mcg orally per day)
- Where
- United States
- Sponsor
- Winthrop University Hospital
Proteinuria
The Effects of Weight Reduction in IgA Nephropathy
The study aims to explore the non-pharmacological treatment of IgA nephropathy by weight reduction. The investigators hypothesized that benefits of weight loss may reduce proteinuria.
- Trial name
- WeightPro (NCT01773382)
- Testing
- weight reduction
- Where
- Thailand
- Volunteers
- 30 people
- Sponsor
- Chulalongkorn University
Chronic Kidney Disease, Proteinuria
Sitaxsentan in Proteinuric Chronic Kidney Disease
Patients with chronic kidney disease (CKD) have higher blood pressures than the general population. They also tend to have protein leaking into the urine (proteinuria).
- Conditions
- Chronic Kidney Disease, Proteinuria, Blood Pressure
- Trial name
- NCT00817037
- Testing
- Sitaxsentan, Nifedipine
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- University of Edinburgh